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fusion. The treatment was designed with SmartArc with 
multiple arches made with Synergy. The dosage regimen used 
is Lagerwaard one: [RCT (20 Gy) + SIBmts (40 Gy)] / 5 frac. 
Positioning of the patient was checked daily with conebeam. 
Before starting the optimization we must be contoured 3mm 
ring around the calote we call follicles, and a contraction of 
the outer contour of 12mm we call volume CPE. We define 
two arcs (VMAT CCW 178 ° -60 ° and 300 ° -182 °), with the 
following objectives: follicles (DSEmax = 16 Gy, weight = 20; 
DSEmax = 5 Gy, weight = 1), brain-CPE (Dmax = 21Gy, weight 
= 100 and Dmin = 20 Gy, weight = 50), eyes (Dmax = 10 Gy, 
weight = 1). Later, we focus on separate metastases: 
optimization blocked prophylaxis (Optimization Type None) 
and create three structures: VI1 = PTV (MTS1) 5 mm VI2 = 
PTV (m2) 5 mm Epx = brain-VI1-VI2 . The objectives were 
PTVI (Dmax = 44Gy, despite Dmin = 100 and = 40 Gy weight = 
50), Epx (Dmax = 30 Gy) and brainstem (Dmax = 23Gy), 
follicles (DSEmax = 16 Gy, weight = 20 ; DSEmax = 5 Gy, 
weight = 1)  
Verifying treatment was performed with the Compass 
software, and the Matrixx detector with gamma (4%, 1 mm) 
conditioning. 
 
Results: So far we have treated 15 patients, the differences 
in the images of fusion of less than 1 mm and the average 
correction IGRT of 1.24mm. No acute toxicity. Nor alopecia, 
or temporary removal, 
 
Conclusion: If we consider our VMAT optimization alopecia in 
WBRT + SIB with eXaFrame and eXaSkin, produce optimal 
aesthetic results. 
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Purpose or Objective: To describe clinical outcomes of 
hypofractionated radiotherapy, either in combination or not 
with temozolomide (TMZ) in poor performance status 
glioblastoma (GBM) patients 
 
Material and Methods: We retrieved the charts of 96 patients 
treated with hypofractionated radiotherapy plus/minus TMZ 
for GBM at our Institution 
 
Results: Patients characteristics were summarized in Table 1.  
 
 
Among elderly patients, 38 (71.6%) were treated with RT 
alone, 9 patients (16.9%) with adjuvant TMZ, while 6 patients 
(11.3%) with a KPS ≥70 received hypoRT plus concurrent TMZ, 
followed by adjuvant chemotherapy in 3 (5.6%) of these 
cases. The median follow up time of the entire cohort was 
13.6 months (range 1-47 months). A significant improvement 
in KPS from baseline to the end of radiation therapy was 
observed in 73 patients (76%). The median overall survival 
time was 6.7 months, reducing to only 2.5 months and 4 
months respectively in elderly and younger patients with low 
performance status (KPS<70). The 6 months and 1 year 
survival rates were respectively 56.4% and 29.1%. In 
multivariate analysis, concomitant Temozolomide (HR:0.38, 
95% CI 0.16-0.85,p=.020) and adjuvant TMZ (HR:0.28,95% CI 
0.14-0.56,p=.000) emerged as significant indices of longer OS 
rates, while weaning from steroids (p=.18), extent of surgical 
resection (p=.17) and tumor site (p=.10) were not significant 
predictors of overall survival but showed a positive trend. 
Patients who received concomitant TMZ had a median 
survival time of 12.5 months compared with 6.3 months for 
those treated with RT alone (p=.017). Also the use of 
adjuvant chemotherapy resulted in improved survival 
compared to no sequential Temozolomide (10.8 vs 5.2 
months, p=.001). In the elderly cohort, patients treated with 
adjuvant TMZ had median OS of 8.15 months as opposed to 
6.4 months of those not receiving adjuvant chemotherapy 
(p=.001). A stronger impact of adjuvant TMZ has been 
reported in younger patients, with a median OS of 13.5 
months in adjuvant TMZ group compared to 3.7 months 
(p=.001) in the other group. Moreover, younger patients 
receiving concurrent Temozolomide showed a significantly 
longer OS of 20 months compared to 5.1 months in patients 
not having TMZ (p=.006). Acute tolerance to radiotherapy 
was generally good. No grade 3-4 acute toxicity was 
observed. 
 
Conclusion: Our findings seem to suggest that frail elderly 
patients with KPS at baseline < 70 do not benefit of an active 
treatment and could be carefully offered best supportive 
care. In the presence of a good functional status and a wide 
surgical resection, patients older than 65 years may take 
advantage of hypo-fractionated radiotherapy, followed by 
adjuvant TMZ. In younger patients with poor performance 
status, the significant survival gains obtained with combined 
modality treatment suggest that a maximum resection 
followed by combined radiation and chemotherapy should be 
recommended.  
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Purpose or Objective: Assessment of tolerance of combined 
modality therapy of patients with malignant gliomas 
irradiated using IMRT technique. We compared dose 
distribution in IMRT and conformal 3D treatment plans. 
 
Material and Methods: Between 2009 and 2013 in the 
Oncology Center in Krakow 60 patients with malignant 
gliomas received combined modality treatment. Mean age 
was 53 years (range 24–72 years). All patients were in good 
performance status (WHO 0–1). There were 48 patients with 
glioblastoma multiforme and 12 with anaplastic astrycytoma. 
48 patients underwent complete resection and 12 partial 
resection. Patient were irradiated using IMRT technique with 
a total dose of 60Gy in 30 fractions. All patients concurrently 
received temozolamide in the dose of 75mg/m2. In all 
patients we performed additional plans using 3D conformal 
